Clinical Trial Update: Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 [Phase 3]

View source ↗

Summary

Phase 3 trial update on antibody persistence and safety/tolerability of a booster dose for the meningococcal B vaccine after completion of the primary vaccinati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Meningococcal B vaccine (Meningococcal B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningoccocal Disease, Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2018-12-07